JP2015526409A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015526409A5 JP2015526409A5 JP2015520289A JP2015520289A JP2015526409A5 JP 2015526409 A5 JP2015526409 A5 JP 2015526409A5 JP 2015520289 A JP2015520289 A JP 2015520289A JP 2015520289 A JP2015520289 A JP 2015520289A JP 2015526409 A5 JP2015526409 A5 JP 2015526409A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cdr
- amino acid
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 41
- 125000003275 alpha amino acid group Chemical group 0.000 claims 35
- 208000024827 Alzheimer disease Diseases 0.000 claims 11
- 238000002600 positron emission tomography Methods 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 238000009792 diffusion process Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- MYNQXTDIPMCJCR-HUYCHCPVSA-N 2-[2-fluoranyl-6-(methylamino)pyridin-3-yl]-1-benzofuran-5-ol Chemical compound [18F]C1=NC(NC)=CC=C1C1=CC2=CC(O)=CC=C2O1 MYNQXTDIPMCJCR-HUYCHCPVSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000037259 Amyloid Plaque Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000031864 metaphase Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000000700 radioactive tracer Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261667891P | 2012-07-03 | 2012-07-03 | |
| US61/667,891 | 2012-07-03 | ||
| PCT/US2013/046399 WO2014007982A2 (en) | 2012-07-03 | 2013-06-18 | C-terminal and central epitope a-beta antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015526409A JP2015526409A (ja) | 2015-09-10 |
| JP2015526409A5 true JP2015526409A5 (enExample) | 2016-08-04 |
Family
ID=49882576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520289A Abandoned JP2015526409A (ja) | 2012-07-03 | 2013-06-18 | Ｃ−末端及び中心エピトープａ−ベータ抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150353631A1 (enExample) |
| EP (1) | EP2869846A4 (enExample) |
| JP (1) | JP2015526409A (enExample) |
| KR (1) | KR20150036163A (enExample) |
| CN (1) | CN105579061A (enExample) |
| AU (1) | AU2013287119A1 (enExample) |
| BR (1) | BR112014033066A2 (enExample) |
| CA (1) | CA2877516A1 (enExample) |
| HK (1) | HK1208810A1 (enExample) |
| IL (1) | IL236549A0 (enExample) |
| MX (1) | MX2014015744A (enExample) |
| RU (1) | RU2014153675A (enExample) |
| WO (1) | WO2014007982A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3078121A1 (en) * | 2013-09-13 | 2015-03-19 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| BR112017001385B1 (pt) | 2014-07-22 | 2023-12-05 | Cb Therapeutics, Inc. | Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão |
| ES2987034T3 (es) | 2014-08-05 | 2024-11-13 | Apollomics Inc | Anticuerpos anti-PD-L1 |
| US20180344881A1 (en) * | 2015-11-20 | 2018-12-06 | Navidea Biopharmaceuticals, Inc. | Formulations for 2-heteroaryl substituted benzofurans |
| KR102799807B1 (ko) * | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| CN105542005B (zh) * | 2016-02-03 | 2018-11-09 | 大连理工大学 | 一种抗人淀粉样β肽的纳米抗体及其应用 |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| ES2971881T3 (es) | 2016-08-19 | 2024-06-10 | Beigene Switzerland Gmbh | Combinación de zanubrutinib con un anticuerpo anti-cd20 o anti-pd-1 para su uso en el tratamiento del cáncer |
| US11555038B2 (en) | 2017-01-25 | 2023-01-17 | Beigene, Ltd. | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| US11597768B2 (en) | 2017-06-26 | 2023-03-07 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| CN116348487A (zh) | 2020-07-23 | 2023-06-27 | 欧萨尔普罗席纳有限公司 | 抗淀粉样β抗体 |
| CN118382636A (zh) | 2021-12-17 | 2024-07-23 | 豪夫迈·罗氏有限公司 | 一种用于检测淀粉样蛋白β42(Aβ42)的新抗体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9125798A (en) * | 1997-08-28 | 1999-03-16 | University Of Washington | Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| SK288723B6 (sk) * | 2000-02-24 | 2020-01-07 | Univ Washington | Farmaceutický prostriedok a použitie tohto farmaceutického prostriedku |
| TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| WO2005018424A2 (en) * | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
| AR051800A1 (es) * | 2004-12-15 | 2007-02-07 | Wyeth Corp | Anticuerpos a beta usados en mejorar la cognicion |
| US20060210557A1 (en) * | 2005-01-28 | 2006-09-21 | Donna Luisi | Stabilized liquid polypeptide formulations |
| MY167887A (en) * | 2005-12-12 | 2018-09-26 | Ac Immune Sa | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| US20100239570A1 (en) * | 2007-09-13 | 2010-09-23 | Roger Nitsch | Moncolonal amyloid beta (abeta) - specific antibody and uses thereof |
| WO2011133919A1 (en) * | 2010-04-22 | 2011-10-27 | Janssen Alzheimer Immunotherapy | Use of tau to monitor immunotherapy |
| WO2011106732A1 (en) * | 2010-02-25 | 2011-09-01 | Wyeth Llc | Pet monitoring of ab-directed immunotherapy |
-
2013
- 2013-06-18 JP JP2015520289A patent/JP2015526409A/ja not_active Abandoned
- 2013-06-18 BR BR112014033066A patent/BR112014033066A2/pt active Search and Examination
- 2013-06-18 RU RU2014153675A patent/RU2014153675A/ru not_active Application Discontinuation
- 2013-06-18 HK HK15109545.4A patent/HK1208810A1/xx unknown
- 2013-06-18 CN CN201380035339.9A patent/CN105579061A/zh active Pending
- 2013-06-18 US US14/410,018 patent/US20150353631A1/en not_active Abandoned
- 2013-06-18 CA CA2877516A patent/CA2877516A1/en not_active Abandoned
- 2013-06-18 WO PCT/US2013/046399 patent/WO2014007982A2/en not_active Ceased
- 2013-06-18 AU AU2013287119A patent/AU2013287119A1/en not_active Abandoned
- 2013-06-18 KR KR20157001775A patent/KR20150036163A/ko not_active Withdrawn
- 2013-06-18 MX MX2014015744A patent/MX2014015744A/es unknown
- 2013-06-18 EP EP13812620.6A patent/EP2869846A4/en not_active Withdrawn
-
2015
- 2015-01-01 IL IL236549A patent/IL236549A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015526409A5 (enExample) | ||
| CN109219615B (zh) | 识别tau的抗体 | |
| RU2014153675A (ru) | Антитела к с-концевым и центральным эпитопам а-бета | |
| CN109415434B (zh) | 识别tau的抗体 | |
| JP2014511179A5 (enExample) | ||
| Cynis et al. | Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges | |
| JP2013521233A5 (enExample) | ||
| JP2013538796A5 (enExample) | ||
| JP2016512551A5 (enExample) | ||
| JP2019505527A5 (enExample) | ||
| JP2020512281A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| JP2022506719A (ja) | タウ認識抗体 | |
| JP2010526028A5 (enExample) | ||
| JP2009530423A5 (enExample) | ||
| JP2017528476A5 (enExample) | ||
| CN102089430A (zh) | 针对渐进性糖化终极产物受体（rage）的抗体及其用途 | |
| JP2016513682A5 (enExample) | ||
| JP2010520290A5 (enExample) | ||
| JP2016525502A5 (enExample) | ||
| JP2014533357A5 (enExample) | ||
| JP2017537082A5 (enExample) | ||
| JP2013521252A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| CN108431039B (zh) | 改进的p2x7受体结合剂和包含其的多肽 |